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ABSTRACT 
Cocaine Use Disorder (CUD) is a debilitating psychopathology, with no recommended 
medication therapy or specific psychological intervention. Memory-focused cognitive therapy 
(MFCT) is a novel psychotherapy for CUD, theorised to modify and re-consolidate cocaine 
craving-related memories for cognitive and behavioural control. A pilot randomised 
controlled trial indicated that this therapy is associated with reduced craving and cocaine 
use. With an 80% confidence interval set for null hypothesis testing, we conducted an 
exploratory causal mediation analysis with confounder adjustment to determine if increased 
cocaine abstinence following MFCT is mediated by reduced craving experience and 
increased emotion regulation. Participant data on the Difficulties in Emotion Regulation 
Scale did not meet screening evaluation as a potential mediator. Cocaine craving (assessed 
by the frequency version of the Craving Experience Questionnaire) was associated with a 
total treatment effect of MFCT on cocaine abstinence at follow-up (1.499; 80% CI 1.114 to 
1.970; p = 0.012). A significant natural indirect effect indicated that reductions in cocaine use 
were strongly mediated by reduced frequency of craving experience (1.753; CI 80% 1.334 to 
2.936; p < 0.0001). This study provides exploratory evidence in support of the theoretical 
action for MFCT and underscores the importance of craving as a therapeutic target. 
Keywords: cocaine use disorder; craving; memory; reconsolidation; cognitive behavioural 
therapy; mediation 
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INTRODUCTION 
 
Cocaine use disorder (CUD; Diagnostic and Statistical Manual [DSM-5]; American 
Psychiatric Association, 2013) is a debilitating psychopathology. In DSM-5, CUD has 11 
symptoms, spanning increased tolerance, withdrawal symptoms, urges to use cocaine 
(craving) and several behavioural, health and social problems associated with chronic 
consumption.  
 
Among these symptoms, influential models of addiction position the cognitive-affective 
construct – craving – in a key disorder maintaining role (Robinson & Berridge, 1993; Tiffany, 
1990; West, 2006). Craving is a highly subjective construct. It is clear from patient reports 
that the content and strength of craving varies widely. An episode can be brief or protracted 
and distressing. Etiologically, craving can be understood as the product of a drug exposure 
and associative learning process in which previously drug-neutral situations, objects, people, 
sensations/moods that present when cocaine is obtained become conditioned stimuli ([CS]; 
O'Brien, Childress, McLellan, & Ehrman, 1992). An encountered CS (or a direct drug-related 
cue such as the sight of cocaine or cocaine paraphernalia) can trigger a process of cognitive 
elaboration in which memory of past drug use – often in the form of a vivid sensory mental 
image (May et al., 2014; May, Andrade, Panabokke, & Kavanagh, 2004) – induces a desire 
for pleasure, or the need to alleviate anxiety, stress, or cocaine-related withdrawal symptoms 
(Baker, Piper, McCarthy, Majeskie, & Fiore, 2004; Koob, Caine, Parsons, Markou, & Weiss, 
1997). Negative reinforcement, in particular, can be very strongly motivating for some people 
with CUD, leading to problems with the regulation of emotion (Cheetham, Allen, Yucel, & 
Lubman, 2010; Fox, Axelrod, Paliwal, Sleeper, & Sinha, 2007). 
 
In CUD, cocaine-related imagery can drive the maintenance of pro-drug (approach) thoughts, 
appraisals and dysfunctional beliefs (Andrade, May, & Kavanagh, 2012; Conway, Meares, & 
Standart, 2004). These cue-induced responses can persist long into abstinence and, if not 
controlled, can cause relapse (Parvaz, Moeller, & Goldstein, 2016). It is also important to 
recognise that if a person with CUD has immediate access to cocaine, there may be minimal 
or no craving-related elaboration (Tiffany, 1990). However, if there is a delay in obtaining 
cocaine, or there is ambivalence with the desire to be abstinent, craving is likely to be strong, 
distressing and highly motivating (Kavanagh, Andrade, & May, 2005).  
 
There have been many efforts to develop an effective therapy for CUD. However, to date 
there are no licensed medications or guideline-recommended specific psychosocial 
interventions (National Institute for Health and Care Excellence, 2007). Among the latter, 
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Cognitive Behavioural Therapy (CBT) has been the most widely trialled intervention. A meta-
analysis of 53 randomised controlled trials targeting alcohol or another drug disorder 
calculated that stand-alone CBT is associated with a small overall standardised mean 
difference for the treatment effect versus control (Hedge’s g = 0.154; Magill & Ray, 2009). A 
more encouraging picture emerged when the authors pooled results from trials that 
combined CBT with another psychosocial intervention (typically general drug counselling). 
This strategy was associated with a medium effect size (g = 0.305; p < 0.005; 19 trials).  
 
The population of cocaine users is heterogenous. Some powder cocaine users use 
infrequently, but there is a sub-population who use smokable (crack) cocaine or cocaine 
powder very intensively and develop CUD; many with considerable unmet treatment need. In 
England in 2016-2017, it was estimated that there were 760,000 powder cocaine users and 
181,000 crack users in the general population (Home Office, 2017; Public Health England, 
2017a). In that year, 42,403 people presented to community addiction treatment clinics for 
help with cocaine-related problems (16,892 powder cocaine and 25,511 crack) of whom 52% 
had a co-occurring opioid use disorder (Public Health England, 2017b). Community services 
offer people with CUD general counselling, but many do not engage with this intervention or 
discontinue treatment after a short time. Among those who are retained in treatment, 
continued crack cocaine use is a significant predictor of poor response to medication for 
opioid use disorder (Marsden et al. 2012; Marsden et al. 2019).  
 
Against this background – and encouraged by the potential for a CBT intervention to be 
effective when offered alongside ongoing general counselling and support – we developed a 
novel cognitive therapy intervention with the goal of helping people to better recognise, 
modify and control cocaine craving-related thoughts, emotions and behaviour. Our Memory-
Focused Cognitive Therapy (MFCT) is a 15-week, outpatient, individual psychotherapy 
(Marsden et al., 2017). In addition to a formulation-driven assessment and cognitive 
restrucuring and behavioural experiments, MFCT adapts to CUD the fear memory reliving, 
imagery re-scripting and memory reconsolidation paradigm successfully used for the 
treatment of post-traumatic stress disorder (Brewin, Gregory, Lipton, & Burgess, 2010; Grey, 
Young, & Holmes, 2002; Holmes & Mathews, 2010). Our MFCT therapy protocol also 
includes a cue-induction procedure to elicit images and affective responses as therapy 
targets (Hon, Das, & Kamboj, 2016; Xue et al., 2012). 
 
In psychotherapy, an important part of the evidence-gathering process for a new intervention 
is to address theoretical hypotheses of how treatment causes change (Kazdin, 2007; 
Murphy, Cooper, Hollon, & Fairburn, 2009). This is typically done by conducting a causal 
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mediation analysis (Hayes, 2014; MacKinnon, 2008). A causal mediation analysis tests 
whether there is evidence that the psychotherapy exposure is related to changes in a 
hypothesised mediator, and whether the mediator is associated with changes in a 
subsequent outcome. A randomised controlled trial provides the logical design conditions for 
causal inference because participants are randomly allocated to the levels of the therapeutic 
exposure.  
 
Prior to the analysis of the developmental study (Marsden et al., 2018), the statistical 
analysis plan for the primary and secondary outcome measures was pre-registered (Centre 
for Open Science; https://www.osf.io/3kfzj/). The results showed that compared to an 
assessment-only control, the intervention was associated with lower levels of craving (bias 
corrected Hedge’s g = -1.62; 95% CI -2.45 to -0.80; the primary outcome measure) and more 
abstinent days (g = 1.19; 90% CI 0.54 to 1.84; the drug use secondary outcome measure). In 
that report, we stated our plan to determine if craving and emotion regulation mediate 
cocaine use, thereby giving evidence of the MFCT’s theoretical change mechanism.  
 
In this article we present the results of an exploratory causal mediation analysis to estimate 
the extent to which MFCT is associated with cocaine abstinence through craving experience 
and emotion regulation. We predict that reduced craving and improved emotion regulation 
mediates observed treatments effects of MFCT at follow-up. 
 
METHODS 
 
Design, setting and participants 
Data for the present study were from a completed and published single-site, 15-week, two-
arm, randomised controlled trial contrasting MFCT (the intervention; n=16) to an assessment 
and cocaine cue-induction only group (the control; n=14).  
 
The published protocol provides a detailed description of the study procedures and 
interventions (Marsden et al., 2017). Briefly, the intervention comprised 3x90 minute pre-
randomisation assessments; 2x30 minute cocaine cue-induction procedures; 5x120 minute 
individual MFCT sessions over consecutive days; and 3x60 minute MFCT-relapse prevention 
discussions and research follow-ups at one-week, one-month and three-months conducted 
as personal interviews at the clinic. The control group received the three-session pre-
randomisation assessment, the two cue-induction procedures, and participated in the three 
research follow-ups only. 
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The trial was done at an English National Health Service (NHS) community addictions clinic 
operated by South London and Maudsley Trust and at the National Institute for Health and 
Research and Wellcome Trust Clinical Research Facility (CRF) at King’s College Hospital, 
London. Ethical approval for the protocol was granted by the UK National Research Ethics 
Service.  
 
Patients (aged 18 years and over) receiving ongoing general drug counselling were eligible 
for the trial if they were diagnosed with CUD (Structured Clinical Interview for DSM-5; First, 
Williams, Karg, & Spitzer, 2015). Study exclusion criteria were current non-abstinent alcohol 
use disorder1; uncontrolled severe mental health disorder; current PTSD2; and suicide 
planning in the past month or a suicide attempt in the past six months. All patients provided 
their informed written consent.  
 
Measures  
The following clinical research measures were used for the analysis (see Figure 1 for timing 
during the study): 
 
Difficulties in Emotional Regulation Scale (Gratz & Roemer, 2004). The DERS is a 36-
item self-report measure of current emotion regulation. It includes four components: 
awareness and understanding; acceptance; ability to control impulses in the presence of 
negative affect; and access to emotion regulation strategies. Items are rated using a five-
point scale (almost never to almost always; 0-5; total score: 36-180). Higher scores indicate 
more difficulty in emotion regulation. Participants completed the DERS at 1-month follow-up 
and the instrument was screened as a potential mediator for the analysis. 
 
The Craving Experience Questionnaire – frequency version (May et al., 2014). The 
CEQ-F is an 11-item, self-report measure of the frequency of intensity, imagery and 
intrusiveness aspects of craving in the past two weeks (adapted for the present study). Each 
item is rated using an 11-point scale (0-10; total score: 0-110). Participants completed the 
CEQ-F at baseline and at 1-month follow up and the instrument was screened as a potential 
mediator for the analysis. 
 
                                                          
1 People with non-abstinent alcohol use disorder were judged at risk of presenting to the CRF with 
intoxication at a level precluding admission (alcohol breath test screening to a maximum of 30 mg/ml).  
2 In the original protocol, we were concerned that a patient with untreated PTSD might not be able to 
accept or have a negative reaction to a memory relieving procedure, so this exclusion was on safety 
grounds. 
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Treatment Outcomes Profile (Marsden et al., 2008). The TOP is a structured, clinician 
administered interview for substance use disorder treatment outcome research. It includes a 
calendar prompt, time-line follow-back method to record drug use during the prior 28 days. 
Participants completed the TOP at baseline and three-month follow-up. The outcome 
measure for the analysis was the number (count) of days abstinent (NDA) from cocaine at 
the 3-month follow-up. 
 
Urine Drug Screen (UDS; Alere Toxicology). To indicate recent drug use at the 3-month 
follow up (and to verify self-report using Cohen’s kappa statistic), we used an instant result 
immunoassay device to detect the primary cocaine metabolite (benzoylecgonine) in urine.  
 
Statistical analysis  
Some description is warranted on our conceptual approach for the causal mediation analysis. 
Rather than follow the traditional method of assessing mediation (Baron & Kenny, 1986), we 
used the counterfactual framework (Valeri & Vanderweele, 2013; VanderWeele, 2015).  
In Baron and Kenny’s regression equation approach (see Figure 2, panel 1), path c' 
represents the direct effect of the exposure on the outcome. Path a' estimates the effect of 
the exposure on the mediator and path b’ shows the effect of the mediator on outcome. 
Taken together, path a' and b' express the indirect effect of the exposure on the outcome via 
the mediator. This approach has served researchers very well – but it cannot estimate 
exposure-mediator interactions or handle non-continuous outcome measures (Holland, 
1986).  
VanderWeele’s counterfactual framework was developed to address these limitations (see 
Figure 2, panel 2). Here, the estimation of effects is achieved by comparing observed and 
hypothetical outcomes for the intervention and control groups, on the assumption of 
‘exchangeability’ (i.e. that people assigned to the control group [A=0] would respond in the 
same way as people assigned to the intervention group [A*=1] had they been assigned to the 
intervention, and vice versa; (Robins & Greenland, 1992).  
 
A causal mediation model decomposes the total effect (TE) into a direct effect (i.e. the effect 
of treatment [A] on outcome [Y; A=0 versus A*=1]) and the natural indirect effect (NIE). There 
are two types of direct effect – a controlled direct effect (CDE) and a natural direct effect 
(NDE). The CDE is computed by holding the mediator to a constant. The NDE is computed 
by holding the mediator to the unexposed (control) level, allowing for natural variation. The 
CDE and NDE are equivalent unless there is an exposure-mediator interaction. The NIE 
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captures the effect of the mediation pathway (i.e. the average change in Y if the exposure is 
fixed to the level of the intervention and the mediator changes accordingly [i.e. A=0 to A*=1]; 
VanderWeele, 2015). 
 
All analysis was done in Stata (version 15.0; StataCorp, 2017) in four steps. First, the data 
was screened using Little's test (command: mcartest), with the intention to use multiple 
imputation (command: mice) to manage missing values provided that missingness was 
independent of the unobserved and observed data.  
Second, we compared baseline and 1-month follow-up values between the groups on 
variables for the analysis, with a 95% CI for the comparison of measures at 1-month follow-
up because this was the level precision set for the primary outcome in the original trial.  
Thirdly, univariate regression models were fitted to demonstrate significant associations 
between treatment and mediator; mediator and outcome; and treatment and outcome – each 
fitted univariably and multivariably to identify potential confounding. At baseline, the following 
participant measures were used as covariates: sex, age, months of regular cocaine use, 
months of general drug counselling and CEQ-F score.  
Finally, the causal mediation analysis was done using the command paramed (Dunn et al., 
2015). Paramed supports use of count-based outcome measurement (as used here), and 
gives standard errors (SE), confidence intervals (CI) and parameter estimates for the TE, 
CDE, NDE, and NIE by the delta method. Given the small sample size and exploratory 
nature of the analysis, these parameters were estimated by bootstrapping with 80% 
confidence intervals for hypothesis testing.  
 
RESULTS  
Participant enrolment and missing data 
Fifty-eight patients were screened for the study of whom 35 were enrolled. As planned, 30 
participants completed the assessment phase and were randomised to the control group 
(n=14) and the intervention group (n=16).  
All participants completed the 1-month follow-up, except one member of the control group 
who declined to complete the DERS. All participants, bar one from each group, completed 
the 3-month follow-up. A non-significant Little’s test statistic supported use of multiple 
imputation for the missing DERS total score (χ2 [16] = 14.50; p = 0.561), and the two missing 
values on the NDA outcome (χ2 [36] = 11.38; p = 1.000).  
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Baseline characteristics and group differences on emotion regulation and craving  
There was good group balance on baseline characteristics (Table 1). The overall CEQ-F 
sample mean at baseline was 62.7 (SD 20.2). The CEQ-F had good internal reliability 
(Cronbach’s alpha 0.83). The overall sample mean for the DERS at baseline was 103.3 (SD 
26.29) with excellent internal reliability (alpha 0.93).  
Table 2 shows the summary values on the variables for the causal mediation model at 
baseline and the two follow-ups, by group.  
At baseline, there were no group differences on the measures of cocaine use, CEQ-F and 
DERS. Compared to the control group, participants in the intervention group had lower CEQ-
F scores at 1-month follow-up (g = -1.62; 80% CI -0.80 to -2.45). The intervention was also 
associated with greater NDA at the 3-month follow-up (g = 0.38; 80% CI 0.30 to 1.28). There 
was complete concordance between self-report and UDS data (i.e. all participants who 
reported cocaine use in the past 7 days had a cocaine positive UDS, and all participants who 
reported no cocaine use in the past 7 days had a negative UDS; kappa = 1.00).  
For the DERS, there was no statistically significant group difference at 1-month follow-up (g = 
-0.45; 80% CI -0.93 to 0.02).  
Causal mediation analysis  
Assumptions for Mediation  
Univariate regression models were first fitted to each model pathway. Separate linear 
regression models tested the direct effect of treatment on the mediator (path a') to meet 
assumptions for mediation. The intervention was associated with lower scores on the CEQ-F 
at 1-month follow-up (F [1,28] = 20.99; adjusted R2 = 0.408; p < 0.0001). However, the 
intervention was not associated with any meaningful change on the DERS (F [1,28] =1.63; 
adjusted R2 = 0.021; p = 0.212).  
To test the effect of the CEQ-F on 3-month NDA outcome, a Poisson regression model was 
fitted to the NDA outcome. Lower CEQ-F scores at 1-month were associated with greater 
cocaine abstinence (Likelihood Ratio [LR] X2 [1] = 80.67; p<0.0001; Pseudo R2 = 0.252). The 
intervention was also associated with increased NDA at three months (LR X2 [1] = 21.16; 
p<0.0001; Pseudo R2=0.066). Higher DERS score at 1-month was associated with less 
abstinence at 3-months (LR X2 [1] = 27.73; p<0.0001; Pseudo R2 = 0.087). However, since 
the DERS scores at 1-month were not associated with the intervention, it did not meet the 
minimum requirement for mediation and this variable was dropped from further analysis.  
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Identification of Covariates  
Table 3 shows the results of univariable and covariate-adjusted regression models. The 
univariable models fitted indicated that months of regular cocaine use (p=0.035), baseline 
CEQ-F (p = 0.030) and trial group (p < 0.0001) were all univariable predictors of 1-month 
CEQ-F score. However, in the multivariable model only trial group was associated with CEQ-
F score (adjusted R2 0.479; p = 0.002).  
Age (p = 0.001), months of regular cocaine use (p = 0.003), baseline CEQ-F (p < 0.0001), 
baseline cocaine use (p < 0.0001), and trial group (p < 0.0001) were all predictors of change 
on the outcome. Then, in an adjusted model (Pseudo R2 0.201), sex (p = 0.043), baseline 
CEQ-F (p = 0.006), baseline cocaine use (p = 0.001), and trial group (p < 0.0001) were all 
associated with outcome.  
Based on the adjusted models for 1-month craving and 3-month cocaine abstinence, sex, 
baseline CEQ and baseline cocaine use were included in the final model as potential 
confounders (Table 4). The model was run bootstrapped with 10,000 replications.  
Mediation Analysis 
Overall, there was a significant association of the intervention on NDA outcome (TE 1.499; 
80% CI 1.114 to 1.970; p=0.012). With no evidence of an exposure-mediator interaction, the 
CDE and NDE are equivalent, and NDE is reported only herein.  
There was no evidence of a significant direct effect (NDE = 0.855; 80% CI 0.569 to 1.175; p 
= 0.242) and a rate ratio coefficient close to 1 indicated little-to-no difference between 
participants receiving the intervention or control through the model’s direct causal pathway. 
This was underscored by the Poisson model (Coefficient -0.156; 95% CI -0.419 to -0.106; p = 
0.242). The mediating pathway was significant (NIE = 1.753; 80% CI 1.334 to 2.936; p < 
0.0001) indicating that a reduction in craving at 1-month follow-up was associated with 
increased abstinence in the participants in the intervention group. 
DISCUSSION 
Using data from a randomised controlled trial, we present an exploratory mediation analysis 
providing preliminary evidence for a mediating effect of the frequency of intensity, imagery 
and intrusiveness aspects of cocaine craving (as measured by the CEQ-F) on cocaine 
abstinence among patients allocated to MFCT.  
Both treatment allocation and craving were independently associated with cocaine use and 
after covariate adjustment, study data suggest a causal effect of MFCT on cocaine 
abstinence via reduced craving experience. The significant NIE from the causal mediation 
9 
 
 
 
model provides evidence in support of our hypothesised therapeutic change mechanism. In 
spite of the small sample, this was strong effect: once the effect of craving at one month was 
accounted for, the model showed no statistically significant direct effect of MFCT on 
outcome.  
Based on this analysis, there was no support for the hypothesis that emotion regulation 
mediates cocaine abstinence after therapy. Reduced DERS scores were associated with the 
NDA outcome at 3-month follow-up, but this was an independent effect that was not linked to 
the intervention. However, it would be wrong to miss the opportunity to help patients in this 
area. Previous studies have suggested that individuals with CUD show stronger responses to 
emotional stimuli (Aguilar de Arcos, Verdejo-Garcia, Peralta-Ramirez, Sanchez-Barrera, & 
Perez-Garcia, 2005) and emotion regulation can improve as abstinence is sustained (Fox et 
al., 2007). It is possible that a lack of association between emotion regulation and treatment 
in our study may in part be because the DERS (and the CEQ-F) does not capture 
motivations to use drugs to change emotional state. During assessment and therapy 
sessions, participants collaboratively explored and addressed craving and cocaine use as a 
response to positive and negative mood. Substance use as a strategy for coping with 
negative affect (and associated craving) is likely to play an important role in use and relapse 
and may be a more relevant predictor than the general aspects of emotion regulation 
addressed in the DERS.   
The present analysis supports assessing and targeting craving experience to inform 
psychological treatment of CUD (Marsden et al., 2014). While it is not currently feasible to 
directly target sub-threshold, cue-induced responses, MFCT targets cognitive and affective 
elaborations with the aim of diminishing the strength of future craving experiences. By 
capitalising on the malleability of memory reconsolidation processes, our novel 
psychotherapy appears to reduce drug approach cognitions and responses to cocaine 
conditional cues so that subsequent craving experiences are better controlled (Kavanagh et 
al., 2005). Better cognitive control is likely to increase self-efficacy when exposed to high-risk 
situations (Sklar, Annis, & Turner, 1999), and may lead to reductions in activity in reward 
regions in the brain (Volkow et al., 2010).  
Nevertheless, as we have noted, craving does not always precede cocaine use. Some 
people with CUD, find that cocaine seeking has become highly automatized and if there is 
immediate drug access, there may be minimal, if any, craving and cognitive elaboration. Our 
efforts to help patients become aware of automatic processes may provide some protection 
to enable a process of reflection and alternate action.  
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In the context of the wider literature there is mixed evidence on the role of craving in 
predicting cocaine use and a number of studies have concluded that craving does not 
reliably predict cocaine use (Miller & Gold, 1994; Weiss, Griffin, & Hufford, 1995). However, 
more recent studies favour craving as a predictor of cocaine-seeking (Da Silveira, Doering-
Silveira, Niel, & Jorge, 2006; Preston et al., 2009) and relapse (Crits-Christoph et al., 2007; 
Paliwal, Hyman, & Sinha, 2008; Rohsenow, Martin, Eaton, & Monti, 2007; Sinha, Garcia, 
Paliwal, Kreek, & Rounsaville, 2006; Weiss et al., 2003). The present study contributes to 
and extends this mixed extant literature showing craving as measured by the CEQ-F as a 
strong predictor of cocaine use. 
 
It is important to note that memory reconsolidation interventions are at a relatively early stage 
of development (Exton-McGuinness & Milton, 2018; Monfils & Holmes, 2018). However, the 
literature is growing with encouraging findings from psychological laboratory studies with 
users of nicotine, heroin, alcohol and cocaine (Germeroth et al., 2017; Hon, Das, & Kamboj, 
2016; Xue et al., 2012) and pharmacological interventions (e.g. propranolol; Lonergan et al., 
2016; Saladin et al., 2013; Xue et al., 2017). Taken together, these interventions suggest that 
memory-reconsolidation techniques can reduce craving and subsquent drug-seeking. To our 
knowledge, our study is the first to apply memory reconsolidation approaches in the addiction 
clinic setting. Replication studies by other groups are now warranted.  
Study strengths include the experimental design and control over confounding, along with the 
pre-planned analysis plan, and a counterfactual framework analysis of causal mediation. We 
also acknowledge several limitations. Although in-line with recommendations for pilot studies, 
this was a small sample study and the results must be regarded as exploratory and in need 
of replication. A longer follow-up period up to 12 months is recommended to examine the 
robustness of MFCT-based cocaine abstinence against time, given the relapsing nature of 
CUD. Nevertheless, the present findings are encouraging and give impetus for future 
superiority randomised controlled trials of MFCT alongside general counselling for people 
with primary CUD, and as an adjunctive intervention for patients with concurrent CUD and 
opiate use disorder (Marsden et al. 2019). 
At present, CUD is a significant and hard to treat public health problem with limited treatment 
options and it is crucial to understand the mechanisms underlying potential new treatments. 
This study positions craving as an important mediator in reducing cocaine use in participants 
receiving MFCT. 
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Figure 1: Timing of Study Measures 
 
 
Note:  
CEQ, Craving Experience Questionnaire;  
DERS, Difficulties in Emotion Regulation Scale;  
MFCT, Memory-focused Cognitive Therapy;  
UDS, Urine Drug Screen;  
TOP, Treatment Outcome Profile (time-line follow-back interview for past 28 days). 
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Figure 2. Baron and Kenny mediation model and counterfactual framework 
 
1  Baron and Kenny model 2 Counterfactual framework 
 
 
 
 
 
 
A = exposure, M = mediator, Y = outcome 
A = exposure, M= Mediator, Y = outcome;  
C1 = exposure-outcome confounder,  
C2 = mediator-outcome confounder 
 
Regression model notation: 
 
1) Ε(Y|A=a) = β0+ β1a +e 
2) Ε(M|A=a) = β0+ β1a +e 
3) Ε(Y|M=m A=a) β0+ β1M+e 
4) Ε(Y|A=a) = β0+ β1X+ β2M+e 
 
 
Regression model notation: 
 
RRCDE(m) = exp{( θ1+θ3m)(a-a*) 
RRNDE = exp{( θ1+θ3β0+ θ3β1a*+θ3β’2c+ θ3θ2σ2)(a-a*) 
+0.5 θ32 σ2(a2- a*2)} 
RRNIE = exp{( θ2β1+θ3β1a)(a-a*) 
 
 
Note:  
A, exposure (intervention or control group by random allocation);  
M, mediator (CEQ-F and DERS at 1-month post-intervention follow-up);  
Y, outcome (Number of Abstinent Days [NDA] at 3-month follow-up);  
RR, rate ratio (continuous mediator and Poisson regression given count-based outcome) 
CDE, controlled direct effect; 
NDE, natural direct effect; 
NIE, natural indirect effect. 
 
 
 
 
c 
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Table 1. Participant characteristics at baseline 
 
  
Variable 
Control 
 (n=14) 
Intervention 
(n=16) 
Male  9 (64%) 11 (69%) 
Age, years  45.0 (6.5) 43.3 (6.7) 
Months of regular cocaine use (IQR) 108.0 (69-150) 94.5 (60-120) 
Months in treatment at enrolment (IQR) 5.0 (1.0, 25.5) 8.5 (2.5, 53.5) 
DSM5 CUD diagnosis (severity):    
   Moderate (4-5 symptoms) 4 (29%) 3 (19%) 
   Severe (6-11 symptoms) 10 (71%) 13 (81%) 
Medication for co-occurring opioid use disorder:   
   Oral methadone (mg/day) 5 (55.0) 6 (61.7) 
   Sublingual buprenorphine (mg/day) 4 (13.0) 5 (14.4) 
 
 Note:   
 
 Data are number of participants, mean (SD) or median (IQR, inter-quartile range) 
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Table 2. Variables included in analysis at baseline, one-month follow-up (potential 
mediators) and outcome at 3-month follow-up, by study group (n=30) 
 
Point/variable 
 
Control (n=14) Intervention 
(n=16) 
Difference (95% CI) Effect size (CI) d 
Baseline  M (SD) M (SD)   
  Cocaine NDA a    46.43 (27.98)   45.09 (16.64) -1.34 (-18.30 to 15.62) -0.06 (-0.78 to 0.66) 
  CEQ-F b 67.5 (17.00) 58.5 (22.40)    -9.00 (-24.05 to 6.05) -0.44 (-1.16 to 0.29) 
  DERS c 104.71 (22.28) 102.06 (30.05) -2.65 (-17.38 to 22.68) -0.10 (-0.81 to 0.62) 
1-month follow-up     
  CEQ-F  51.75 (22.72) 14.77 (21.47) -36.98 (-53.51 to -20.45) -1.62 (-0.80 to -2.45) † 
  DERS   98.21 (22.67) 85.50 (30.58)    12.71 (-7.67 to 33.10) -0.45 (-0.93 to 0.02) ‡ 
3-month follow-up     
  Cocaine NDA 51.55 (35.34) 77.07 (27.50) 25.52 (10.44 to 40.59) 0.38 (0.30 to 1.28) ‡ 
 
Note:  
 
M, mean; SD, standard deviation; CI, confidence interval; 
 
a NDA, number of days abstinent from cocaine past 28 days;  
b CEQ-F, Craving Experience Questionnaire (frequency version); recall period: past 2 weeks 
(total score, range: 0-110); 
c DERS, Difficulties in Emotion Regulation Scale; recall period past two weeks (total score, 
range: 36-180); 
d Hedge’s g; 
† Effect size CI advanced specified at 95% CI;  
‡ Effect size CI advanced specified at 80% CI. 
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Table 3. Unadjusted and covariate adjusted causal mediation analysis of treatment exposure 
on cocaine craving and cocaine use outcome at 3-month follow-up. 
Variable/path to mediator Coef.  95% CI SE t P-value 
Unadjusted       
 Sex 3.455 -19.652 to 26.561 11.280 0.31 0.762 
 Age  1.099 -0.533 to 2.730 0.797 1.38 0.179 
 Months in general counselling -16.182 -37.085 to 4.722  10.205 -1.59 0.124 
 Months regular cocaine use  21.970 1.661 to 42.280 9.915 2.22 0.035 
 Baseline CEQ-F a 0.560 0.057 to 1.064 0.246 2.28 0.030 
 Baseline cocaine use -0.989 -2.748 to 0.771 0.859 -1.15 0.259 
 Group  -36.981 -53.515 to -20.446 8.072 -4.58 <0.0001 
Model (R2 0.605; adj. R2 0.479)      
  Sex  1.532 -17.455 to 20.519 9.155  0.17 0.869 
  Age  0.315 -1.000 to 1.630 0.634 0.50 0.624 
  Months in general counselling -11.660 -28.403 to 5.083 0.163 -1.44 0.163 
  Months regular cocaine use 12.645 -6.204 to 31.495 0.178 1.39 0.178 
  Baseline CEQ-F a   0.278 -0.181 to 0.738 0.221  1.26 0.222 
  Baseline cocaine use  -0.493 -2.076 to 1.090 0.763 -0.65 0.525 
  Group -29.290 -46.775 to -11.806 8.431 -3.47 0.002 
Variable/paths to outcome IRR  95% CI SE z P-value 
Unadjusted       
   Sex 1.199 0.997 to 1.441 0.112  1.93 0.053 
   Age 0.979 0.967 to 0.992 0.006 -3.22 0.001 
   Months in general counselling 1.000 0.997 to 1.004 0.002 0.23 0.821 
   Months regular cocaine use 0.773 0.654 to 0.914 0.066 -3.01 0.003 
   Baseline CEQ-F a -0.990 -0.986 to -0.994 0.002 -5.10 <0.0001 
   Baseline cocaine use 1.038  1.023 to 1.053 0.007  5.17 <0.0001 
   CEQ-F at 1-month (mediator) 0.984 0.981 to 0.988 0.002 -8.39 <0.0001 
   Group 1.494  0.1256 to 1.779 0.132  4.53 <0.0001 
Model (Pseudo R2 0.201)      
   Sex 1.238 1.007 to 1.522 0.131 2.02 0.043 
   Age  0.995 0.982 to 1.009 0.007 -0.73 0.466 
   Months in general counselling 1.007 0.840 to 1.209 0.094 0.08 0.937 
   Months regular cocaine use 0.904 0.748 to 1.091 0.087 -1.05 0.292 
   Baseline CEQ-F a 0.994 0.989 to 0.998 0.002 -2.74 0.006 
   Baseline cocaine use 1.030 1.012 to 1.049 0.009 0.006 0.001 
   Group 1.420 1.168 to 1.726 0.141 0.001 <0.0001 
 
Note:  
 
a CEQ-F, Craving Experience Questionnaire (frequency version); recall period: past 2 weeks 
(total score, range: 0-110); 
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Table 4. Causal mediation model, adjusted for covariates 
 
Estimates (Poisson model) Coef.  95% CI SE P-value 
Model (Pseudo R2 0.325)     
Sex 0.200  0.008 to 0.392 0.099 0.041 
Baseline cocaine use 0.021 -0.004 to 0.039 0.010 0.018 
Baseline CEQ-F score  -0.004 -0.008 to 0.001 0.002 0.093 
CEQ-F (mediator) -0.016 -0.021 to -0.011 0.004 <0.0001 
Group -0.156 -0.419 to 0.106 0.134 0.242 
Summary of effects Coef.  80% CI  SE * P-value  
 NDE 0.855 0.569 to 1.175 0.240 0.242 
 NIE 1.753 1.334 to 2.936 0.875 <0.0001 
 Total effect 1.499 1.114 to 1.970 0.356 0.012 
 
 Note:  
NDE, Natural direct effect; equivalent to CDE without mediator-outcome interaction 
  NIE, Natural indirect effect; 
  * Bootstrapped  
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